Compare AVDL & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVDL | GRDN |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Drug Stores and Proprietary Stores |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1996 | 2024 |
| Metric | AVDL | GRDN |
|---|---|---|
| Price | $21.69 | $33.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $19.14 | ★ $33.33 |
| AVG Volume (30 Days) | ★ 1.6M | 270.4K |
| Earning Date | 03-02-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.28 |
| Revenue | $248,517,000.00 | ★ $1,389,638,000.00 |
| Revenue This Year | $65.47 | $19.50 |
| Revenue Next Year | $30.88 | $0.48 |
| P/E Ratio | ★ N/A | $117.91 |
| Revenue Growth | ★ 79.88 | 18.68 |
| 52 Week Low | $6.38 | $17.78 |
| 52 Week High | $23.57 | $37.43 |
| Indicator | AVDL | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 62.23 |
| Support Level | $21.52 | $30.85 |
| Resistance Level | $21.69 | $33.00 |
| Average True Range (ATR) | 0.06 | 1.43 |
| MACD | -0.01 | 0.32 |
| Stochastic Oscillator | 66.67 | 98.07 |
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.